|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Preoperative functional MR imaging localization of language and motor areas: effect on therapeutic decision making in patients with potentially resectable brain tumors显示文摘 | Petrella JR Shah LM Harris KM Friedman AH George TM Sampson JH Pekala JS Voyvodic JT | 2006 | 中国神经肿瘤杂志2006，4，2： | 14 |
| 2 | 重组脊髓灰质炎病毒用于治疗复发胶质母细胞瘤(英文)显示文摘Background The prognosis of patients with recurrent World Health Organization(WHO)grade IV malignant glioma is dismal,and there is currently no effective therapy.We conducted a dose-finding and toxicity study in this population of patients,evaluating convection-enhanced,intratumoral delivery of the recombinant nonpathogenic polio-rhinovirus chimera(PVSRIPO).PVSRIPO recognizes the poliovirus receptor CD155,which is widely expressed in neoplastic cells of solid tumors and in major components of the tumor microenvironment.Methods We enrolled consecutive adult patients who had recurrent supratentorial WHO grade IV malignant glioma,confirmed on histopathological testing,with measurable disease(contrast-enhancing tumor of≥1 cm and≤5.5 cm in the greatest dimension).The study evaluated seven doses,ranging between 107 and 1010 50%tissue-culture infectious doses(TCID50),first in a dose-escalation phase and then in a dose-expansion phase.Results From May 2012 through May 2017,a total of 61 patients were enrolled and received a dose of PVSRIPO.Dose level-1(5.0×107TCID50)was identified as the phase 2 dose.One dose-limiting toxic effect was observed;a patient in whom dose level 5(1010TCID50)was administered had a grade 4 intracranial hemorrhage immediately after the catheter was removed.To mitigate locoregional inflammation of the infused tumor with prolonged glucocorticoid use,dose level 5 was deescalated to reach the phase 2 dose.In the dose-expansion phase,19%of the patients had a PVSRIPO-related adverse event of grade 3 or higher.Overall survival among the patients who received PVSRIPO reached a plateau of 21%(95%confidence interval,11 to 33)at 24 months that was sustained at 36 months.Conclusions Intratumoral infusion of PVSRIPO in patients with recurrent WHO grade IV malignant glioma confirmed the absence of neurovirulent potential.The survival rate among patients who receivedPVSRIPO immunotherapy was higher at 24 and 36 months than the rate among historical controls. | Desjardins A Gromeier M Herndon JE 2nd Beaubier N Bolognesi DP Friedman AH Friedman HS McSherry F Muscat AM Nair S Peters KB Randazzo D Sampson JH Vlahovic G Harrison WT McLendon RE Ashley D Bigner DD | 2018 | 中华神经外科疾病研究杂志2018，17，4： | 2 |
| 3 | Unarmed,tumor-specific monoclonal antibody effectively treats brain tumors显示文摘 | Sampson JH Crotty LE Lee S | 2000 | Proc Natl Acad Sci USA2000，97，13： | 1 |
| 4 | Microvascular decompression for glossopharyngeal neuralgia:long-term effectiveness and complication avoidance显示文摘 | Sampson JH Grossi PM Asaoka K | 2004 | Neurosurgery2004，54，4： | 1 |
| 5 | Surgical management of petroclival meningiomas:defining resection goals based on risk of neurological morbidity and tumor recurrence rates in 137 patients显示文摘 | Little KM Friedman AH Sampson JH | 2005 | Neurosurgery2005，56，3： | 1 |
| 6 | Microvascular decompression for glossopharyngeal neuralgia: long-term effectiveness and complication avoidance 显示文摘 | Sampson JH Grossi PM Asaoka K | 2004 | Neurosurgery2004，54，4： | 1 |
| 7 | An epidermal growth factor receptor variantⅢ-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme显示文摘 | Sampson JH Archer GE Mitchell DA | 2009 | Mol Cancer Ther2009，8，10： | 1 |
| 8 | A genetically modified allogeneic cellular vaccine generates MHC class Ⅰ-restricted cytotoxic responses against tumor -associated antigens and protects against CNS tumors in vivo显示文摘 | Ashley DM Sampson JH Archer GE | 1997 | J Neuro Immunol1997，78，12： | 1 |
| 9 | Unarmed,tumor-specific monoclonal antibody effectively treats brain tumors显示文摘 | Sampson JH Crotty LE Lee S | 2000 | Proc Natl Acad Sci U S A2000，97，13： | 1 |
| 10 | Unarmed,tumor-specific monoclonal antibody effectively treats brain tumors显示文摘 | Sampson JH Crotty LE Lee S | 2000 | Proc Natl Acad Sci USA2000，97，13： | 1 |
| 11 | Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variantⅢpeptide vaccination in patients with diagnosed glioblastoma显示文摘 | Sampson JH Heimberger AB Archer GE | 2010 | J Clin Oncol2010，28，31： | 1 |
| 12 | Microvasculardecompression for glossopharyngeal neuralgia:long-term effectiveness and complication avoidance显示文摘 | Sampson JH Grossi PM Asaoka K | 2004 | Neuro-surgery2004，54，4： | 1 |
| 13 | The PEPvIII-KLH (CDX- 110) vaccine in glioblastoma multiforme patients显示文摘 | Heimberger AB Sampson JH | 2009 | Expert Opin Biol Ther2009，9，8： | 1 |
| 14 | Regional treatment of epidermal growth factor receptor vⅢ-expressing neoplastic meningitis with a single-chain immunotoxin,MR-1显示文摘 | Archer GE Sampson JH Lorimer IA | 1999 | Clin Cancer Res1999，5，9： | 1 |
| 15 | An efide,mal growth factor receptor variant m -targeted vaccine is safe and inmmnogenic in patients with glioblastoma mullifirme 显示文摘 | Sampson JH Archer GE Mitchell DA | 2009 | Mol Cancer Ther2009，8，10： | 1 |
| 16 | Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant Ⅲ peptide vaccination in patients with newly diagnosed glioblastoma显示文摘 | Sampson JH Heimberger AB Archer GE | 2010 | J Clin Oncol2010，28，： | 1 |
| 17 | Microvaseular deco- mpression for glossopharyngeal neuralgia: long-term effectiveness and complication avoidance 显示文摘 | Sampson JH Grossi PM Asaoka K | 2004 | Neurosurgery2004，54，： | 1 |
| 18 | Unarmed,tumor specific moncolomal antibody effectively treats brain tumors显示文摘 | Sampson JH Crotty LE Lee S | 2000 | Proc Natl Acad Sci USA2000，97，13： | 1 |
| 19 | Surgical management of petmclival meningiomas: defining resection goals based on risk of neurological morbidity and tumor recurrence rates in 137 patients 显示文摘 | Little KM Friedman AH Sampson JH | 2005 | Neurosurgery2005，56，3： | 1 |
| 20 | Viruses in the treatment of brain tumors显示文摘 | Fecci PE Gromeier M Sampson JH | 2002 | Neuro Clin N Am2002，12，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员